Results 41 to 50 of about 436,454 (294)

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Molecular evaluation of the anticancer potential of 1,3,4-oxadiazole-2-thiones derivative and its synergetic action with Nigella sativa seed extract (Thymoquinone) in experimentally induced Murine Lung Cancer Cell Line Model. [PDF]

Journal of Medical and Life Science
Lung cancer persistently poses as a primary factor in cancer-linked deaths globally, necessitating novel treatment strategies. This investigation appraises the anti-tumor potential of Thymoquinone (TQ) and 1,3,4-oxadiazole derivatives independently and ...
Abdel Aziz Zidane, Elsayed Mahmoud, Mahmoud Tarek, El-Hassan Mokhamer   +3 more
doaj   +1 more source

CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses [PDF]

, 2021
Katie E. Lineburg, Emma J. Grant, Srividhya Swaminathan, Demetra S.M. Chatzileontiadou, Christopher Szeto, Hannah Sloane, Archana Panikkar, Jyothy Raju, Pauline Crooks, Sweera Rehan, Andrea Nguyen, Lea Lekieffre, Michelle A. Neller, Zhen Tong, Dhilshan Jayasinghe, Keng Yih Chew, Christian A. Lobos, Hanim Halim, Jacqueline M. Burrows, Alan Riboldi‐Tunnicliffe, Weisan Chen, Lloyd D’Orsogna, Rajiv Khanna, Kirsty R. Short, Corey Smith, Stéphanie Gras   +25 more
openalex   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

The significance of CD4+ and CD8+ T lymphocyte infiltration in esophageal squamous cell carcinoma

Indian Journal of Pathology and Microbiology
Purpose: To investigate the relationship between the abundance of CD4+ and CD8+ T cells in the tumor microenvironment and the prognosis of patients with esophageal squamous cell carcinoma, and to analyze their correlation and explore its clinical value ...
Jiang Y. Zhao, Xiaojun Pang, Jiao Peng, Jingtao Liu, Qiang Deng, Shunhai Jian   +5 more
doaj   +1 more source

Higher Expression of Activated CD8+ T Lymphocytes (CD8+CD25+, CD8+CD69+ and CD8+CD95+) Mediate Early Post-Transplant Acute Tubular Injury in Kidney Recipients

Frontiers in Bioscience-Landmark, 2023
Background: Acute kidney injury (AKI) is a leading cause of early post-transplant kidney damage. Furthermore, acute tubular necrosis (ATN) is appointed as the most prevalent form of AKI, a frequent multifactorial process associated with high morbidity and mortality, yet giving rise to delayed graft function (DGF) and, ultimately, allograft dysfunction.
Manuel Muro, Santiago Llorente, Alfredo Minguela, Jesús de la Peña-Moral, Maria R. Moya-Quiles, Rafael Alfaro, Isabel Legaz, Víctor Jimenez-Coll, Francisco Boix   +8 more
openaire   +3 more sources

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer

OncoImmunology, 2019
Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood.
Katsunobu Hagihara, Stephen Chan, Li Zhang, David Y. Oh, Xiao X. Wei, Jeffry Simko, Lawrence Fong   +6 more
doaj   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source